EIP bags cash to trial ex-Vertex drug in dementia, Huntington's by Nick Paul Taylor Monday, April 15, 2019 The cash will fund midphase trials of an ex-Vertex drug in dementia and Huntington's disease.
EIP Pharma nabs $20.5M to push Alzheimer's drug through phase 2 by Amirah Al Idrus Wednesday, May 16, 2018 EIP Pharma is enrolling a phase 2b trial of neflamapimod, which targets synaptic dysfunction.